factMR-logo.png
Cancer Supportive Care Product Market is Set to Surge at 6.9% CAGR, to Reach US$ 68.93 Billion by 2034 | Fact.MR
September 24, 2024 06:00 ET | FACT.MR
Rockville, MD, Sept. 24, 2024 (GLOBE NEWSWIRE) -- In its new study, Fact.MR states that the global cancer supportive care product market is estimated to reach a value of US$ 35.47 billion in 2024...
visiongain Logo.png
Bile Duct Cancer Drugs Market Report Up to 2031: Visiongain Research Inc
January 12, 2022 10:00 ET | Visiongain Ltd
Visiongain has published a new report on Bile Duct Cancer Drugs Market Report to 2031. Profiles of Leading Bile Duct Cancer Drugs Market players, Regional and Leading National Market Analysis. PLUS,...
provectus_logo.jpg
PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY
April 18, 2018 06:00 ET | Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 18, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a clinical-stage...
SNS FiRe Conference
SNS FiRe Conference Names Atrin Pharmaceutical a 2016 FiReStarter Company
June 09, 2016 10:00 ET | Future In Review
SEATTLE, WA--(Marketwired - June 09, 2016) - Strategic News Service (SNS) has selected Atrin Pharmaceutical, Doylestown, PA, as a 2016 FiReStarter company to be featured at the 14th annual Future in...
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
June 17, 2010 09:00 ET | Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - June 17, 2010) -  Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...
Marshall Edwards' CEO to Present at Needham Healthcare Conference
June 03, 2010 08:00 ET | Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) -  Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Announces Grants Under Nasdaq Rule 5635
April 29, 2010 08:00 ET | Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 29, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards Appoints New President and CEO
April 26, 2010 08:00 ET | Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
March 31, 2010 08:00 ET | Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
February 08, 2010 08:00 ET | Marshall Edwards, Inc.
SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced that Christopher Naughton had resigned as a member of the Board of Directors effective February 5,...